Showing 41-50 of 235 results for "".
Practice Cost Savings, Part III: Technology
https://practicaldermatology.com/topics/practice-management/practice-cost-savings-part-iii-technology/21525/From health records to IT, technology presents practices with unique challenges and opportunities for savings.Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
https://practicaldermatology.com/programs/cme/closing-arguments-in-the-case-of-targeted-versus-ici-adjuvant-treatment-of-stage-iii-melanoma/15908/tbdCharles Crutchfield III, MD, FAAD
https://practicaldermatology.com/topics/practice-management/charles-crutchfield-iii-md-faad/21433/Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
https://practicaldermatology.com/programs/cme/defense-argument-for-single-agent-ici-adjuvant-treatment-of-stage-iii-melanoma/15907/tbdOpening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
https://practicaldermatology.com/programs/cme/opening-statements-in-the-case-of-targeted-versus-ici-adjuvant-treatment-of-stage-iii-melanoma/15905/tbd- Hanaa Khadraoui, OMS-IIIhttps://practicaldermatology.com/profiles/hanaa-khadraoui-oms-iii/7ZKVnv/
- DeAnna Diaz, MS, MBS, OMS-IIIhttps://practicaldermatology.com/profiles/deanna-diaz-ms-mbs-oms-iii/jG8Ek5/
- Sarah Li, OMS-IIIhttps://practicaldermatology.com/profiles/sarah-li-oms-iii/j56okn/
Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentCosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.